Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 1
1975 1
1976 1
1977 4
1978 6
1979 5
1980 4
1982 2
1983 3
1984 9
1985 10
1986 9
1987 3
1988 7
1989 12
1990 7
1991 11
1992 10
1993 4
1994 16
1995 16
1996 12
1997 10
1998 10
1999 8
2000 13
2001 12
2002 17
2003 18
2004 14
2005 12
2006 12
2007 22
2008 19
2009 23
2010 28
2011 15
2012 25
2013 41
2014 47
2015 49
2016 46
2017 49
2018 46
2019 45
2020 69
2021 63
2022 75
2023 71
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

922 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Lymphoma"
Page 1
NK-/T-cell lymphomas.
Wang H, Fu BB, Gale RP, Liang Y. Wang H, et al. Leukemia. 2021 Sep;35(9):2460-2468. doi: 10.1038/s41375-021-01313-2. Epub 2021 Jun 11. Leukemia. 2021. PMID: 34117356 Free PMC article. Review.
Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein-Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. ...Immune therapies, histone deacetylase (HDAC)-inhibitors and other drugs are in early clinical …
Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein-Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia a …
Primary central nervous system lymphoma.
Schaff LR, Grommes C. Schaff LR, et al. Blood. 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. Blood. 2022. PMID: 34699590 Free PMC article. Review.
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. ...This review provides a discussion of the clinical pr …
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brain, spinal cord, lep …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blocka …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representi …
Conjunctival Lymphoma.
McGrath LA, Ryan DA, Warrier SK, Coupland SE, Glasson WJ. McGrath LA, et al. Eye (Lond). 2023 Apr;37(5):837-848. doi: 10.1038/s41433-022-02176-2. Epub 2022 Jul 26. Eye (Lond). 2023. PMID: 35882984 Free PMC article. Review.
Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have improved clinicians' ability to predict future recurrence or systemic disease through assessment of cytogenic and molecular features. In th …
Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have …
Follicular lymphoma: The long and winding road leading to your cure?
Gordon MJ, Smith MR, Nastoupil LJ. Gordon MJ, et al. Blood Rev. 2023 Jan;57:100992. doi: 10.1016/j.blre.2022.100992. Epub 2022 Jul 23. Blood Rev. 2023. PMID: 35908982 Review.
Advances in biologic understanding of molecular events in lymphoma cells and the tumor microenvironment, along with novel cellular and targeted therapies, suggest this may soon change. ...We then focus on developments over the last decade in further defining follicu …
Advances in biologic understanding of molecular events in lymphoma cells and the tumor microenvironment, along with novel cell …
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Martelli M, et al. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30. Crit Rev Oncol Hematol. 2013. PMID: 23375551 Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. ...The combination of the anti-CD20 monoclonal antibody rituximab and CHOP chemotherapy, every 14 or 21 days, is the standard treatmen …
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Count …
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P, Wang ML. Jain P, et al. Am J Hematol. 2022 May;97(5):638-656. doi: 10.1002/ajh.26523. Am J Hematol. 2022. PMID: 35266562 Free article.
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer treatments. MCL consists of a spectrum of clinical subtypes. Rarely, atypical cyclin D1-negative MCL and …
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis …
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
BACKGROUND: Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with v …
BACKGROUND: Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced …
CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R. Pasqui DM, et al. Eur J Haematol. 2022 Dec;109(6):601-618. doi: 10.1111/ejh.13851. Epub 2022 Sep 18. Eur J Haematol. 2022. PMID: 36018500 Review.
Additionally, four randomized controlled trials comparing CAR-T cell therapy to the standard treatment for various types of relapsed/refractory B cell non-Hodgkin lymphomas and multiple myeloma included in this systematic review still did not have available outcome …
Additionally, four randomized controlled trials comparing CAR-T cell therapy to the standard treatment for various types of relapsed/ …
Limited-stage diffuse large B-cell lymphoma.
Hawkes EA, Barraclough A, Sehn LH. Hawkes EA, et al. Blood. 2022 Feb 10;139(6):822-834. doi: 10.1182/blood.2021013998. Blood. 2022. PMID: 34932795 Free article. Review.
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized in 25% to 30% of patients. ...This comprehensive review provides an update of recent literature with recommendations for integration into clinical practice for LS-DLB …
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized in 25% to 30% of patients. ...Thi …
922 results